Indication
Lymphocyte-Depleted Classic Hodgkin Lymphoma (Ann Arbor Stage I)
1 clinical trial
6 products
Clinical trial
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)Status: Active (not recruiting), Estimated PCD: 2024-09-23
Product
BleomycinProduct
Brentuximab VedotinProduct
DacarbazineProduct
DoxorubicinProduct
NivolumabProduct
Vinblastine